Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Britain Courts Anthropic Amid US Defense Department Dispute 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
LA JOLLA, Calif., Sept. 02, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Wednesday, September 7, 2016 at 12:00 p.m. PDT (3:00 p.m. EDT). The conference will be held from September 7-8, 2016 in San Francisco.
A live audio webcast and replay will be available in the Investors section of Kura Oncology's corporate website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
